HanYu Pharmaceutical: Simetaglucagon injection is expected to complete clinical trials within the year.

HanYu Pharmaceutical announced on November 10th on the interactive platform that the company's Simeglutide injection for weight management and glycemic control indications are both in Phase III clinical trials. All subjects have been enrolled, have received medication and follow-up, and have entered the final stage. It is expected to complete the clinical trial by the end of the year.